---
title: "Hold Rating Reiterated on Moderna as Analyst Keeps $49 Price Target Amid Long-Term Pipeline Potential and Near-Term Execution Risks"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290971983.md"
description: "Goldman Sachs analyst Salveen Richter reiterated a Hold rating on Moderna with a $49 price target, citing long-term pipeline potential balanced against near-term execution risks. While Moderna's Science Day highlighted promising oncology and autoimmune programs, key readouts are delayed until 2027. The primary near-term catalyst is Phase 3 data for the Merck-partnered therapy intismeran. Citi also maintained a Hold rating with a lower $41 target."
datetime: "2026-06-26T12:35:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290971983.md)
  - [en](https://longbridge.com/en/news/290971983.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290971983.md)
---

# Hold Rating Reiterated on Moderna as Analyst Keeps $49 Price Target Amid Long-Term Pipeline Potential and Near-Term Execution Risks

In a report released yesterday, Salveen Richter from Goldman Sachs maintained a Hold rating on Moderna, with a price target of $49.00.

### TipRanks' Prime Week Sale - 70% Off

-   Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
-   Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.

Salveen Richter has given his Hold rating due to a combination of factors that balance Moderna’s long-term opportunities with near-term execution risk. While the company’s Science Day showcased a broadening oncology and autoimmune pipeline, many of the highlighted programs, including the multi-antigen T-cell engager and cancer antigen therapies, remain in early stages with key readouts pushed into 2027 and beyond.

Richter sees the Merck-partnered individualized neoantigen therapy, intismeran, as the primary near-term catalyst, with upcoming Phase 3 adjuvant melanoma data likely to drive the stock’s direction. At the same time, the intact $49 price target reflects both confidence in the mRNA platform’s scalability and caution around the competitive landscape, long development timelines, and the need for disciplined spending and partnerships to fund expansion into oncology and autoimmune indications.

According to TipRanks, Richter is a 5-star analyst with an average return of 11.2% and a 47.53% success rate. Richter covers the Healthcare sector, focusing on stocks such as Moderna, Regeneron, and Agios Pharma.

In another report released today, Citi also maintained a Hold rating on the stock with a $41.00 price target.

### Related Stocks

- [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md)
- [MRK.US](https://longbridge.com/en/quote/MRK.US.md)
- [MRNX.US](https://longbridge.com/en/quote/MRNX.US.md)
- [MRNY.US](https://longbridge.com/en/quote/MRNY.US.md)
- [GS.US](https://longbridge.com/en/quote/GS.US.md)
- [REGN.US](https://longbridge.com/en/quote/REGN.US.md)
- [AGIO.US](https://longbridge.com/en/quote/AGIO.US.md)
- [C.US](https://longbridge.com/en/quote/C.US.md)
- [W4VR.SG](https://longbridge.com/en/quote/W4VR.SG.md)
- [C-R.US](https://longbridge.com/en/quote/C-R.US.md)

## Related News & Research

- [Moderna Maintained at Hold as Analyst Weighs Leading mRNA Platform Against Early-Stage Pipeline Risks](https://longbridge.com/en/news/290970667.md)
- [This Stock Has Already Doubled This Year and Is Still Racing Towards a Major Catalyst](https://longbridge.com/en/news/290916339.md)
- [Moderna spotlights expanding mRNA pipeline at Science Day event](https://longbridge.com/en/news/290819631.md)
- [Moderna publishes Science Day 2026 presentation](https://longbridge.com/en/news/290839905.md)
- [Moderna advances in vivo CAR-T candidate mRNA-6007 into early development for autoimmune diseases](https://longbridge.com/en/news/290822266.md)